Study: Tequin raises risk of both low, high blood sugar

Canadian researchers say they have discovered the antibiotic Tequin, made by Bristol-Myers Squibb, carries a higher risk of both low and high blood sugar when compared with other antibiotics. A co-author of the study published in the New England Journal of Medicine said researchers found Tequin users have nearly 17 times the risk of high blood sugar and more than four times the risk of low blood sugar than people who were on other antibiotics.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX